Dysmenorrhea

Acetaminophen overdose is a leading cause of liver injury, but it is largely preventable

Retrieved on: 
Wednesday, April 26, 2023
Toxicity, Waterloo, New Zealand, University, Bleeding, Awareness, Eating disorder, Urine, Arthritis, Parent, Fever, COVID-19, Sleep, Paracetamol, Dysmenorrhea, Larissa, Liver injury, Medicine, Liver transplantation, Tylenol, Abdominal pain, Pain, Vomiting, Bruise, Cold medicine, Pharmacist, Back pain, Time, Risk, Frailty, Reading, Nausea, Confusion, Drug, Liver, Liver failure, Headache, Death, University of Waterloo School of Pharmacy, Fasting, Skin, Pharmaceutical industry, Dietary supplement, Medicinal plants, Tanning (leather), Pig, Birth control, Pharmacy, Midol

“Larissa was healthy and within a week of the overdose, her liver failed, she received a liver transplant, and died from complications.

Key Points: 
  • “Larissa was healthy and within a week of the overdose, her liver failed, she received a liver transplant, and died from complications.
  • It was probably an attempt to treat her COVID-19 symptoms at a time when she was not eating well.
  • The three of us were developing educational tools on acetaminophen-related liver injury for health-care providers when we first learned of Larissa’s story.

Leading cause of acute liver injury

    • Yet, it is also a leading cause of acute liver injury, which can be fatal without a rescue liver transplant.
    • With millions around the world using acetaminophen every day, why are so few people aware of the dangers of overdose?
    • Approximately 4,500 Canadians are hospitalized from acetaminophen overdose each year — 12 hospitalizations per day.

Toxicity and overdose

    • In the first 24 hours after an overdose, there may only be mild symptoms such as nausea and vomiting, but many have no symptoms at all.
    • While the liver may heal itself, around six per cent of people hospitalized for acetaminophen overdose develop liver failure.
    • An antidote is available (an intravenous medicine called N-acetylcysteine) but it is most effective if given within 24 hours of overdose.

Using acetaminophen safely

    • Given that acetaminophen remains one of the most common medicines for treating pain and fever, people need to take steps to reduce their risk of liver injury.
    • Always check acetaminophen packages for the maximum single dose and 24-hour dose.
    • If the first acetaminophen dose is taken at noon, the 24-hour window ends at noon the next day.
    • When buying acetaminophen for common ailments like a headache or arthritis pain, reach for the regular strength product.

IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.

Retrieved on: 
Monday, March 20, 2023
Premenstrual syndrome, Woman, Research, Dysmenorrhea, Traction, IGC, CUSIP, API, Phase, FDA, Sleep, THC, NYSE, Agitation, EIN, Pharmaceutical industry

POTOMAC, Md., March 20, 2023 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better reflects IGC Pharma’s strategic focus and vision for the future.

Key Points: 
  • POTOMAC, Md., March 20, 2023 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better reflects IGC Pharma’s strategic focus and vision for the future.
  • Our common stock will continue to be quoted on the NYSE American under the same symbol IGC.
  • IGC is currently in a Phase 2 trial with its THC-based investigational medication, IGC-AD1, for the treatment of agitation in Alzheimer’s.
  • IGC also markets a wellness brand, Holief™, that targets women experiencing premenstrual syndrome, menstrual cramps and sleep disorders.

Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1

Retrieved on: 
Wednesday, February 22, 2023
Safety, American College, Adolescence, Dysmenorrhea, Pain, Diclofenac, Peptic ulcer disease, Risk, Vomiting, FDA, Menstruation, Observation, Nonsteroidal anti-inflammatory drug, Primary, Plasma, SAN, Nausea, Vagina, Myometrium, Bloating, Student, Woman, Food, Abdomen, NSAID, USD, Current Problems in Pediatric and Adolescent Health Care, Pharmaceutical industry, Birth control

Primary dysmenorrhea is defined as painful menstruation in women with normal pelvic anatomy, typically described as cramping pain in the lower abdomen before or during the menstrual period.

Key Points: 
  • Primary dysmenorrhea is defined as painful menstruation in women with normal pelvic anatomy, typically described as cramping pain in the lower abdomen before or during the menstrual period.
  • Oral NSAIDs, such as diclofenac, are often recommended for temporary relief from the painful symptoms of primary dysmenorrhea².
  • “The potential benefits of DARE-PDM1 as a potential treatment for the millions of women suffering from primary dysmenorrhea are driven by its unique target product profile,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • “The most common interventions for primary dysmenorrhea include oral NSAIDs and hormonal contraceptives which often can produce undesirable side effects.

Mednow Supports Expanded Scope of Practice for Ontario Pharmacists

Retrieved on: 
Monday, January 23, 2023
Other Health, Health, Pharmaceutical, Telemedicine, Virtual Medicine, Managed Care, Hemorrhoid, Pharmacy, Government, Pharmacist, Dermatitis, Prescription, Dysmenorrhea, Patient, Entrepreneurship, Glycine mollis, Sprain, Impetigo, Nurse practitioner, Urinary tract infection, Inc., Health insurance, Nursing, Franco-Ontarians

Mednow Inc (TSXV: MNOW) (OTCQX:MDNWF), Canada’s on-demand virtual pharmacy is supportive of the new expanded scope of practice for Ontario pharmacists.

Key Points: 
  • Mednow Inc (TSXV: MNOW) (OTCQX:MDNWF), Canada’s on-demand virtual pharmacy is supportive of the new expanded scope of practice for Ontario pharmacists.
  • As of January 1st, pharmacists in Ontario are now able to better support patients by assessing and prescribing treatment for 13 minor conditions.
  • "We are thrilled to see the expanded scope of practice for pharmacists in Ontario," said Ali Reyhany, CEO and Co-Founder of Mednow.
  • The expanded scope of practice for Ontario pharmacists will allow Mednow to expand its virtual care program to include pharmacist-led prescribing.

Covid Hardships Did Not Have a Major Impact on Western European Women's Wellbeing

Retrieved on: 
Tuesday, February 14, 2023
Happiness, Life, Woman, United Kingdom, Family, Diagnosis, Dysmenorrhea, COVID-19, Birth, Uterine fibroid, Work, Health, Index, Condom, Menstrual cycle, Pregnancy, Quality of life, Ageing, Birth control, Nursing

While 82% thinks that they can provide security for the family, only 61% cares about the signals of their own body.

Key Points: 
  • While 82% thinks that they can provide security for the family, only 61% cares about the signals of their own body.
  • Regular screenings are part of the everyday life of only one third, but women have been taking disease prevention more seriously.
  • Having a healthy lifestyle and feeling attractive has become more important, while feeling balanced in their lives remained a major factor in determining women's wellbeing."
  • Choosing safe contraception is the most important women's healthcare issue for the respondents, although 31% does not use any protection.

VENA LAUNCHES WING WOMAN CAPSULES

Retrieved on: 
Thursday, February 9, 2023
Science, Viburnum opulus, Woman, PEA, Dysmenorrhea, Pain, Nature, Menstrual cycle, PMS, Cramp, Birth control, Dietary supplement, Viburnum, Innovation

IRVINE, Calif., Feb. 9, 2023 /PRNewswire/ -- Vena, a leader in plant-based wellness products for women, today announced the debut of its innovative Wing Woman capsules. A revolutionary, clinically proven* pain reliever, Wing Woman's 100% plant-based formula leverages intentional ingredients to help relieve aches and pains to support a more comfortable menstrual cycle.

Key Points: 
  • IRVINE, Calif., Feb. 9, 2023 /PRNewswire/ -- Vena , a leader in plant-based wellness products for women, today announced the debut of its innovative Wing Woman capsules.
  • Vena Wing Woman is a powerhouse duo of ingredients that work synergistically to ease common PMS challenges via anti-inflammatory and antioxidant properties.
  • "As a women-led company, Vena is proud to introduce Wing Woman natural PMS relief so our customers can finally have more reliable, comfortable periods," said Vena Co-Founder, Tamra Judge.
  • Vena Wing Woman is available now at www.venacbd.com , where all Vena products are third-party tested, following the brand's standard of clean ingredients, authenticity and uncompromised quality.

Public advisory - Unauthorized health products removed from sale from More to Shoppe Facebook store and seized from its Edson, Alberta, warehouse

Retrieved on: 
Friday, January 20, 2023
Safety, ASA, Pregnancy, Tropical ulcer, Amoxicillin, Diarrhea, Headache, Health, Prescription drug, Cancer, Acne, Face, Tanning, Allergy, Ulcer, Heartburn, Nonsteroidal anti-inflammatory drug, Anaphylaxis, NSAID, Health Canada, Dysmenorrhea, Scar, Stroke, Bed, Pain, Blister, Skin cancer, Sunburn, Sale, Infection, Bacteria, Patient, Birth, Swelling, Plasma protein binding, NPN, Vomiting, Mouth, Gamer, Skin, Natural product, Stomach, Sunlight, DIN, Tretinoin, Itch, Irritation, Pharmacy, Rash, Nausea, Liver failure, Mefenamic acid, Light, Growth, Red, Gastrointestinal bleeding, Drug identification number, Chills, Stinger, Risk, Bleeding, Kidney, Dry, History, Dietary supplement, Pharmaceutical industry, Cosmetics

Health Canada removed various unauthorized health products from sale from More to Shoppe, an online Facebook store, and seized them from its warehouse in Edson, Alberta.

Key Points: 
  • Health Canada removed various unauthorized health products from sale from More to Shoppe, an online Facebook store, and seized them from its warehouse in Edson, Alberta.
  • Consult a health care professional if you have used any of these products and have health concerns.
  • Read product labels to verify that health products have been authorized for sale by Health Canada.
  • You can also check whether products have been authorized for sale by searching Health Canada's Drug Product Database and Licensed Natural Health Product Database .

IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act

Retrieved on: 
Wednesday, December 7, 2022
Medical cannabis, Woman, Annual report, NYSE, Failure, IGC, Dysmenorrhea, Chronic pain, FDA, THC, Pain, Agitation, Legislation, Seizure, Cannabis, Premenstrual syndrome, Drug development, Risk, Dementia, Efficacy, IP, PMS, CBD, Research, Disease, Safety, COVID-19, Drug, Pharmaceutical industry

POTOMAC, Md., Dec. 07, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”), applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act (“the Act”), which was signed into law by President Biden on Friday Dec. 2, 2022.

Key Points: 
  • POTOMAC, Md., Dec. 07, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”), applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act (“the Act”), which was signed into law by President Biden on Friday Dec. 2, 2022.
  • The law provides legislation establishing a new registration process for conducting research on marijuana and for manufacturing marijuana products for research purposes and drug development.
  • “The study and development of cannabis for its potential therapeutic benefits is at the center of our work at IGC-Pharma,” commented Ram Mukunda, CEO of IGC.
  • “For many years, onerous federal barriers have made it difficult to efficiently source and study cannabis for pharmaceutical applications.

IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease

Retrieved on: 
Thursday, December 1, 2022
Cannabis, Health, Neurology, Natural Resources, Clinical Trials, Research, Science, COVID-19, THC, Dementia, Dysmenorrhea, IGC, Agitation, Risk, Symptoms of COVID-19, Certification, Safety, Chronic pain, APOE, Patient, Annual report, Good manufacturing practice, Disease, GMP, Webcast, CYP2C9, Premenstrual syndrome, NYSE, CBD, In Defense of Global Capitalism, Food and Drug Administration Amendments Act of 2007, Efficacy, Failure, Woman, FDA, Metabolism, Pharmaceutical industry, Vaccine

Currently, there is no Food and Drug Administration (FDA) approved drug for treating agitation in dementia related to Alzheimers (Jones et al., 2021).

Key Points: 
  • Currently, there is no Food and Drug Administration (FDA) approved drug for treating agitation in dementia related to Alzheimers (Jones et al., 2021).
  • We believe that IGC-AD1 has the potential to revolutionize the treatment of Alzheimers Disease as the first and only low-dose natural THC-based formulation candidate currently undergoing FDA trials, commented Ram Mukunda, CEO of IGC.
  • Through these and further trials, we look forward to establishing IGC-AD1s efficacy in treating the symptoms related to Alzheimers Disease.
  • IGC-AD1 relies on low-doses of THC, a psychoactive cannabinoid, and another compound as active agents in trials for Alzheimers.

IGC to Present at the RHK 2022 Disruptive Growth Conference

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Dementia, Dysmenorrhea, PMS, Conference, Agitation, IGC, Chronic pain, ET, Annual report, Premenstrual syndrome, NYSE, CBD, Risk, Failure, Woman, Pharmaceutical industry

POTOMAC, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc (NYSE American: IGC) (IGC or the Company) today announced that Ram Mukunda, Chief Executive Officer, will be presenting at the RHK Disruptive Growth Conference in New York City on Monday, December 5 at 11:20 am ET and will be available for one-on-one meetings on Monday, December 5 and Tuesday, December 6.

Key Points: 
  • POTOMAC, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc (NYSE American: IGC) (IGC or the Company) today announced that Ram Mukunda, Chief Executive Officer, will be presenting at the RHK Disruptive Growth Conference in New York City on Monday, December 5 at 11:20 am ET and will be available for one-on-one meetings on Monday, December 5 and Tuesday, December 6.
  • India Globalization Capital Inc. develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimers disease, Parkinsons disease, chronic pain, and pet seizures.
  • IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on June 23, 2022, as if fully incorporated and restated herein.
  • In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.